EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

Chao-Yang Chen, Min Xie, Jun Gong, Ning Yu, Ran Wei, Li-Li Lei, Si-Miao Zhao, Ruo-Ming Li, Xiu Dong, Xiang-Lin Zhang, Ying Zhou, Shuang-Ling Li und 1 weitere

Frontiers in Pharmacology · 28.04.2023 · 14

DOI: 10.3389/fphar.2023.1132367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.04.2023. Verfasst von Chao-Yang Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University First Hospital, Beijing, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Teicoplanin has been extensively used in the treatment for infections caused by gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). However, current teicoplanin treatment is challenging due to relatively low and variable concentrations under standard dosage regimens. This study aimed to investigate the population pharmacokinetics (PPK) characteristics of teicoplanin in adult sepsis patients and provide recommendations for optimal teicoplanin dosing regimens.

Methods

A total of 249 serum concentration samples from 59 septic patients were prospectively collected in the intensive care unit (ICU). Teicoplanin concentrations were detected, and patients’ clinical data were recorded. PPK analysis was performed using a non-linear, mixed-effect modeling approach. Monte Carlo simulations were performed to evaluate currently recommended dosing and other dosage regimens. The optimal dosing regimens were defined and compared by different pharmacokinetic/pharmacodynamic parameters, including trough concentration (C min ), the ratio of 24-h area under the concentration-time curve to the minimum inhibitory concentration (AUC 0-24 /MIC), as well as the probability of target attainment (PTA) and the cumulative fraction of response (CFR) against MRSA.

Results

A two-compartment model adequately described the data. The final model parameter estimates for clearance, central compartment volume of distribution, intercompartmental clearance and peripheral compartment volume were 1.03 L/h, 20.1 L, 3.12 L/h and 101 L, respectively. Glomerular filtration rate (GFR) was the only covariate that significantly affected teicoplanin clearance. Model-based simulations revealed that 3 or 5 loading doses of 12/15 mg/kg every 12 h followed by a maintenance dose of 12/15 mg/kg every 24 h–72 h for patients with different renal functions were required to achieve a target C min of 15 mg/L and a target AUC 0-24 /MIC of 610. For MRSA infections, PTAs and CFRs were not satisfactory for simulated regimens. Prolonging the dosing interval may be easier to achieve the target AUC 0-24 /MIC than reducing the unit dose for renal insufficient patients.

Conclusion

A PPK model for teicoplanin in adult septic patients was successfully developed. Model-based simulations revealed that current standard doses may result in undertherapeutic C min and AUC, and a single dose of at least 12 mg/kg may be needed. AUC 0-24 /MIC should be preferred as the PK/PD indicator of teicoplanin, if AUC estimation is unavailable, in addition to routine detection of teicoplanin C min on Day 4, follow-up therapeutic drug monitoring at steady-state is recommended.

Schlagwörter

Stichwörter der Autor:innen

Monte Carlo simulationdosing optimizationpopulation pharmacokineticssepsisteicoplanin

Autor:innen und Institutionen

  • Department of Pharmacy, Peking University First Hospital, Beijing, China.
  • Department of Critical Care Medicine, Peking University First Hospital, Beijing, China.
  • Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
  • Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
  • Institute of Clinical Pharmacology, Peking University, Beijing, China.

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Chen, C. Y., Xie, M., Gong, J., Yu, N., Wei, R., Lei, L. L., Zhao, S. M., Li, R. M., Dong, X., Zhang, X. L., Zhou, Y., Li, S. L., & Cui, Y. M. (2023). Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1132367

Vancouver

Chen CY, Xie M, Gong J, Yu N, Wei R, Lei LL, et al. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1132367

BibTeX
@article{Chen2023,
  author = {Chen, Chao-Yang and Xie, Min and Gong, Jun and Yu, Ning and Wei, Ran and Lei, Li-Li and Zhao, Si-Miao and Li, Ruo-Ming and Dong, Xiu and Zhang, Xiang-Lin and Zhou, Ying and Li, Shuang-Ling and Cui, Yi-Min},
  title = {Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1132367}
}
Kostenlos starten →